Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer

Feasibility and Latest Outcomes

Harsha R. Mittakanti; James R. Porter


Curr Opin Urol. 2019;29(2):173-179. 

In This Article


R-RPLND continues to evolve as a treatment option for NSGCT, but its feasibility as both primary therapy and in the postchemotherapeutic setting, along with decreased morbidity, has been demonstrated. Head-to-head trials comparing R-RPLND to O-RPLND would provide much needed high-level evidence illustrating the differences with regards to complications and oncologic effectiveness. Ultimately, much like for O-RPLND, R-RPLND comes down to the experience of the surgeon, and it should be performed by those with significant expertise at high-volume centers.